使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2026 earnings conference call. (Operator Instructions) I would now like to turn the conference over to your host, Mike Czapar, Senior Vice President of Investor Relations. Please go ahead.
各位女士先生,感謝您稍候,歡迎參加禮來 2026 年第一季財報電話會議。(接線員指示) 現在我想把會議交給本次會議主持人——投資人關係資深副總裁 Mike Czapar。請開始。
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2026 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations.
早安。感謝各位參加禮來公司(Eli Lilly and Company)2026 年第一季財報電話會議。我是投資人關係資深副總裁 Mike Czapar。
Joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Lucas Montarce, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific and Product Officer; Adrienne Brown, President of Lilly Immunology; Dr. Carole Ho, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly USA and Global Customer Capabilities; Jake Van Naarden, President of Lilly Oncology and Head of Business Development; Patrik Jonsson, President of Lilly International; and Ken Kuster, President of Lilly CardioMetabolic Health. We're also joined by the Investor Relations team, Jim Greffet, Susan Hedgeland, Mark Heumann, and Wes Taul.
今天與我一同出席的有:禮來董事長暨執行長 Dave Ricks;財務長 Lucas Montarce;首席科學與產品長 Dan Skovronsky 博士;禮來免疫學總裁 Adrienne Brown;禮來神經科學總裁 Carole Ho 博士;禮來美國區總裁暨全球客戶能力負責人 Ilya Yuffa;禮來腫瘤學總裁暨商務發展主管 Jake Van Naarden;禮來國際總裁 Patrik Jonsson;以及禮來心臟代謝健康總裁 Ken Kuster。同時也有投資人關係團隊成員 Jim Greffet、Susan Hedgeland、Mark Heumann 與 Wes Taul 一同參與。
During this call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to various factors, including those listed on slide 4. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent filings with the SEC.
在本次電話會議中,我們預期將根據目前的預期提出預測與前瞻性陳述。由於各種因素,我們的實際結果可能與之有重大差異,包括投影片 4 所列因素。關於可能導致實際結果出現重大差異之因素的更多資訊,載於我們最新的 Form 10-K 以及後續向美國證券交易委員會(SEC)提交的文件中。
The information we provide about our products and pipeline is for the benefit of the investment community, intended to be promotional or otherwise influencing prescribing decisions. As we transition to our prepared remarks, please note, our commentary will focus on non-GAAP financial measures.
我們提供的產品與研發管線資訊係為投資社群之利益所提供,並非意在促銷或以其他方式影響處方決策。在進入預先準備的發言前,請注意,我們的評論將聚焦於非 GAAP 財務衡量指標。
Now I'll turn the call over to Dave.
現在我把電話交給 Dave。
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Thanks, Mike. 2026 is off to a strong start. During the quarter, we delivered robust revenue growth, advanced our pipeline across all four therapeutic areas, announced multiple business development transactions, and invested to drive our future growth. Earlier this month, we achieved an important milestone as orforglipron was approved by the US FDA under the trade name Foundayo.
謝謝你,Mike。2026 年開局強勁。本季我們實現了強勁的營收成長、在四大治療領域全面推進研發管線、宣布多項商務發展交易,並持續投資以驅動未來成長。本月稍早,我們達成一項重要里程碑:orforglipron 已獲美國 FDA 核准,商品名為 Foundayo。
Foundayo has been proven highly effective for weight management, offering the benefits of GLP-1 therapy in a pill form and can be taken at any time of day without food or water restrictions. Foundayo is a new molecule, a new modality for agonizing GLP-1. And it's a new brand. This is the first time a new incretin medicine has been launched with obesity as its indication first.
Foundayo 已證實在體重管理方面高度有效,以口服錠劑形式提供 GLP-1 治療的效益,且可在一天中任何時間服用,不受食物或飲水限制。Foundayo 是一種新分子、也是以新方式作用於 GLP-1 的新療法形式。而且它是一個新品牌。這是首次有新的腸泌素(incretin)藥物以肥胖作為首要適應症上市。
While the Foundayo launch has just begun, we're encouraged by momentum against our 2026 launch priorities. These are broad digital and traditional distribution availability, high levels of awareness with consumers of this new option for weight management, educating a broad group of HCPs, helping them start new patients and get comfortable with a new GLP-1 molecule.
雖然 Foundayo 的上市才剛開始,但我們對照 2026 年上市優先事項所展現的動能感到鼓舞。這些優先事項包括:廣泛的數位與傳統通路可近性、讓消費者高度認知這個新的體重管理選項、教育廣泛的醫療照護專業人員(HCPs),協助他們啟動新病患並熟悉這個新的 GLP-1 分子。
And of course, building broad access in commercial, Medicare via the bridge program, and later Medicaid access for patients. And while the US approval is an important first step, there are over one billion people around the world with obesity and related conditions that could be helped by taking an incretin like Foundayo.
當然,也包括在商業保險、透過橋接計畫的 Medicare,以及後續的 Medicaid 中,為病患建立廣泛的可近性。而美國核准雖是重要的第一步,但全球有超過十億人罹患肥胖及相關疾病,可能可透過像 Foundayo 這樣的腸泌素藥物獲益。
Recall that a key advantage of Foundayo is scalability and that oral GLP-1s for obesity have not yet been introduced outside the US. Regulatory reviews are ongoing in over 40 countries for obesity and type 2 diabetes. And we plan to submit Foundayo in the US for type 2 diabetes later this quarter.
請記得,Foundayo 的一項關鍵優勢是可擴充性(scalability),而用於肥胖的口服 GLP-1 藥物在美國以外尚未推出。目前在超過 40 個國家針對肥胖與第二型糖尿病的法規審查仍在進行中。我們也計畫在本季稍晚於美國提交 Foundayo 的第二型糖尿病適應症申請。
Included in the US type 2 diabetes submission will be the results from the ACHIEVE 4 trial, which we shared a few weeks ago. In the seventh positive Phase 3 registration trial, Foundayo showed cardiovascular safety and the lower risk of all-cause death in adults with type 2 diabetes and obesity without increased cardiovascular risk.
美國第二型糖尿病申請將包含 ACHIEVE 4 試驗的結果,我們在幾週前已分享。在第七項呈陽性的第三期註冊試驗中,Foundayo 顯示具心血管安全性,且在未增加心血管風險的情況下,降低第二型糖尿病合併肥胖成人的全因死亡風險。
In addition to the obesity and diabetes programs, we're actively studying Foundayo in six Phase 3 programs in other diseases, and we will continue to generate new data for this important new medicine in quarter in the quarters and years to come.
除肥胖與糖尿病計畫外,我們也正積極在其他疾病中進行 Foundayo 的六項第三期研究計畫;未來幾季與幾年,我們將持續為這項重要新藥產出更多新數據。
On slide 5, you will -- we list the Q1 financial metrics and the highlights of our progress related to the strategic deliverables of Lilly. Revenue grew 56% compared to Q1 2025. Our key products currently defined as Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound grew by more than $7 billion. Within key products, our immunology, oncology, and neuroscience medicines collectively grew by 160% compared to the same quarter last year as we continue to invest to drive growth across all of our therapeutic areas.
在投影片 5 上,我們列出第一季的財務指標,以及與禮來策略交付項目相關的進展重點。營收較 2025 年第一季成長 56%。我們目前定義的關鍵產品——Ebglyss、Inluriyo、Jaypirca、Kisunla、Mounjaro、Omvoh 與 Zepbound——合計成長超過 70 億美元。在關鍵產品中,我們的免疫學、腫瘤學與神經科學藥物合計較去年同期成長 160%,我們也持續投資以推動所有治療領域的成長。
In addition to the progress on Foundayo, we achieved several key pipeline milestones since our last earnings call, including positive Phase 3 data for Jaypirca in combination with a time-limited regimen in adults with previously treated CLL; positive Phase 3 data for Ebglyss in pediatric atopic dermatitis; positive Phase 3 data for Taltz plus Zepbound in adults with psoriasis and obesity; positive Phase 3 data for retatrutide in adults with type 2 diabetes; and the initiation of a new Phase 3 programs for eloralintide, sofetobartin mypatecan, and brinepatide.
除了 Foundayo 的進展外,自上次財報電話會議以來,我們也達成多項研發管線的重要里程碑,包括:Jaypirca 與限時療程(time-limited regimen)合併用於既往治療過的 CLL 成人之第三期正面數據;Ebglyss 用於兒科異位性皮膚炎之第三期正面數據;Taltz 加上 Zepbound 用於乾癬合併肥胖成人之第三期正面數據;retatrutide 用於第二型糖尿病成人之第三期正面數據;以及啟動 eloralintide、sofetobartin mypatecan 與 brinepatide 的新第三期研究計畫。
Consistent with our capital allocation strategy to expand investments in business development, we announced agreements to acquire multiple companies with clinical stage programs. Orna Therapeutics, a company with an in vivo CAR T pipeline to treat autoimmune diseases. Centessa Pharmaceuticals, a company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurologic conditions.
依循我們擴大商務發展投資的資本配置策略,我們宣布協議收購多家擁有臨床階段計畫的公司。Orna Therapeutics:一家擁有體內(in vivo)CAR T 研發管線、用於治療自體免疫疾病的公司。Centessa Pharmaceuticals:一家正在開發新一類藥物,用於治療過度日間嗜睡及其他神經系統疾病的公司。
Kelonia Therapeutics, a company developing an in vivo platform to treat multiple myeloma in other cancers. And Ajax Therapeutics, a company developing next-generation JAK inhibitors for people with blood cancers. We expect to remain active in business development to complement our internal portfolio, while maintaining the discipline to create shareholder value. We also distributed $1.5 billion in dividends in the first quarter and executed $2.4 billion in share repurchases.
Kelonia Therapeutics:一家正在開發體內平台,用於治療多發性骨髓瘤及其他癌症的公司。以及 Ajax Therapeutics:一家正在為血液癌症患者開發下一代 JAK 抑制劑的公司。我們預期將持續積極進行商務發展,以補強內部產品組合,同時維持創造股東價值的紀律。我們也在第一季發放 15 億美元股利,並執行 24 億美元的庫藏股回購。
Two important updates occurred this quarter to expand access to obesity medications. First, we launched Lilly Employer Connect. This is a platform introduced as a new way for employers to offer obesity management medicines to their employees. While it's still very early for this innovative model, we're encouraged by the level of employer interest.
本季有兩項重要更新,有助於擴大肥胖藥物的可近性。第一,我們推出 Lilly Employer Connect。這是一個平台,作為雇主為員工提供肥胖管理藥物的新方式。雖然這個創新模式仍在非常早期階段,但我們對雇主的興趣程度感到鼓舞。
Second, CMS announced the extension of the Medicare GLP-1 bridge program, which provides access to obesity medicines to people with Medicare. The program will begin no later than July 1, 2026, and run through December 2027. This program has the potential to help improve the health of millions of seniors while capping their out-of-pocket costs at $50 per month.
第二,CMS 宣布延長 Medicare GLP-1 橋接計畫,該計畫為 Medicare 受益人提供肥胖藥物的可近性。該計畫將不晚於 2026 年 7 月 1 日開始,並持續至 2027 年 12 月。此計畫有潛力在將自付費用上限設定為每月 50 美元的同時,協助改善數百萬名長者的健康。
Now I'll turn the call over to Lucas to review our Q1 financial results.
現在我把電話交給 Lucas,請他回顧我們第一季的財務結果。
Lucas Montarce - Chief Financial Officer, Executive Vice President
Lucas Montarce - Chief Financial Officer, Executive Vice President
Thanks, Dave. As shown on slide 6, Q1 was another strong quarter of financial performance. Revenue grew 56% compared to Q1 2025, driven by Zepbound and Mounjaro and solid momentum across all therapeutic areas and geographies. Gross margin as a percentage of revenue was 82.6% in Q1, a decrease of approximately 1 percentage point versus the same quarter last year. The change was driven primarily by low (inaudible) prices.
謝謝,Dave。如投影片6所示,第一季在財務表現方面再度繳出強勁的一季。營收較2025年第一季成長56%,主要由Zepbound與Mounjaro帶動,且在所有治療領域與各地區皆展現穩健動能。第一季毛利率(占營收比)為82.6%,較去年同期約下降1個百分點。此變動主要由較低的(聽不清)價格所致。
Marketing, selling and administrative expenses increased 19% as we continue to invest in promotional activities to support ongoing and planned new product launches. R&D expenses increased 28%, driven by continued investments in our pipeline, including 42 active Phase 3 programs.
行銷、銷售與管理費用增加19%,因我們持續投資推廣活動,以支持進行中及規劃中的新產品上市。研發費用增加28%,主要由我們持續加碼產品線(pipeline)投資所帶動,其中包含42項進行中的第三期(Phase 3)計畫。
Our non-GAAP performance margin was 50% and an increase of approximately 7 percentage points from Q1 2025, driven by revenue growth. Non-GAAP earnings per share was $8.55 including acquired R&D charges of $0.52. This compares to non-GAAP earnings per share of $3.34 in Q1 2025, inclusive of $1.72 of acquired R&D charges.
我們的非GAAP績效利潤率為50%,較2025年第一季提高約7個百分點,主要受營收成長帶動。非GAAP每股盈餘為8.55美元,其中包含0.52美元的併購研發費用(acquired R&D)費用。此與2025年第一季非GAAP每股盈餘3.34美元相比,當期包含1.72美元的併購研發費用。
On slide 7, we quantify the effect of price, rate and volume on revenue growth. US revenue increased 43% in Q1, primarily driven by volume growth from Zepbound and Mounjaro as well as contributions from our immunology, oncology and neuroscience portfolio. US price declined by 7%, including the impact of the previously announced direct-to-patient prices for Zepbound. US price was positively impacted by a one-time adjustments to estimates for rebates and discounts, primarily impacting Zepbound and Mounjaro. Excluding this impact, US price will have declined 10%.
在投影片7,我們量化價格、匯率與銷量對營收成長的影響。美國第一季營收成長43%,主要由Zepbound與Mounjaro帶動的銷量成長,以及我們免疫、腫瘤與神經科學產品組合的貢獻。美國價格下降7%,其中包含先前已公告之Zepbound直接面向病患(direct-to-patient)價格的影響。美國價格亦受到一次性調整(對回扣與折扣估計值的調整)的正面影響,主要影響Zepbound與Mounjaro。若排除此影響,美國價格將下降10%。
Europe revenue grew 37% in constant currency, driven by sustained strong volume growth of Mounjaro. In Japan, revenue grew 42% in constant currency driven by Mounjaro for type 2 diabetes. In China, revenue growth accelerated with the inclusion of Mounjaro on the national reimbursement drug list for type 2 diabetes. And in Rest of the World, revenue more than doubled in constant currency as Mounjaro achieved rapid share gains in Latin America and Asia.
歐洲營收以固定匯率計成長37%,主要由Mounjaro持續強勁的銷量成長所帶動。日本營收以固定匯率計成長42%,主要由Mounjaro用於第二型糖尿病所帶動。中國方面,隨著Mounjaro納入第二型糖尿病的國家醫保藥品目錄,營收成長加速。而在世界其他地區,營收以固定匯率計超過翻倍,因Mounjaro在拉丁美洲與亞洲快速提升市占。
On slide 8, we provide an update on the performance of our key products. Within immunology, we continue to increase our presence in atopic dermatitis with Atlas. US new patient starts increased by 90% compared to Q1 2025. and we steadily gained share within the specialty dermatology market. We continue to focus on patient activation and expanding HCP engagement to drive additional case each area of market.
在投影片8,我們提供關鍵產品表現的最新進展。在免疫領域,我們持續提升Atlas在異位性皮膚炎的市場能見度。美國新病患起始治療人數較2025年第一季增加90%,且我們在專科皮膚科市場穩步提升市占。我們持續聚焦病患啟動(activation)並擴大醫療專業人員(HCP)互動,以推動各市場領域的進一步成長。
In oncology, Jaypirca posted a strong quarter of growth, gathering additional momentum in the US from the expanded post-BTK indication in CLL. Worldwide sales grew 79% compared to Q1 2025, and we continue to hear positive feedback from physicians globally. We believe Jaypirca has the potential to be a foundational therapy across multiple settings and regimens within CLL.
在腫瘤領域,Jaypirca本季成長強勁,並因CLL中擴大至BTK後治療適應症,在美國累積更多動能。全球銷售額較2025年第一季成長79%,且我們持續聽到全球醫師的正面回饋。我們相信Jaypirca有潛力成為CLL多種治療情境與療程組合中的基礎性療法。
Although it's still early, Inluriyo performance in the US was encouraging during its first full quarter launch, achieving over 35% share of ral-cert new patient starts in metastasis breast cancer in Q1. Oral-cert market growth also increased, largely driven by the launch of Inluriyo.
雖然仍屬早期,Inluriyo在美國於上市後首個完整季度的表現令人鼓舞,第一季在轉移性乳癌的ral-cert新病患起始治療中取得超過35%的市占。Oral-cert市場成長亦有所提升,主要由Inluriyo上市所帶動。
In neuroscience, Kisunla continues to be the US leader in amyloid-targeting therapies. The market continues to steadily increase as diagnostic capabilities for Alzheimer's disease expand. We expect European launches to begin contributing to growth throughout 2026. Finally, in cardiometabolic, Mounjaro and Zepbound global revenue was $12.8 billion combined, contributing $6.7 billion of growth compared to Q1 2025.
在神經科學領域,Kisunla持續為美國類澱粉蛋白(amyloid)標靶療法的領導者。隨著阿茲海默症診斷能力擴大,市場持續穩步成長。我們預期歐洲上市將在2026年期間開始對成長做出貢獻。最後,在心臟代謝領域,Mounjaro與Zepbound全球合計營收為128億美元,較2025年第一季增加67億美元的成長貢獻。
As seen on slide 9, the US incretin analog market continued robust growth in Q1. The recent approval of oral GLP-1s expanded the market, enabling more people to benefit from the GLP-1s. Within the US incretin analog obesity market, total prescriptions grew by over 80% in Q1. And Zepbound prescriptions grew at even faster rate.
如投影片9所示,美國腸泌素類似物(incretin analog)市場在第一季持續強勁成長。近期口服GLP-1獲准擴大了市場,使更多人能受益於GLP-1。在美國腸泌素類似物減重市場中,第一季總處方量成長超過80%。而Zepbound處方成長速度更快。
Zepbound performance was driven by continued strong uptick in self-pay channel as well as steady growth in the Commercial segment. However, the loss of Medicaid access in certain states had a negative impact on Q1 prescription growth in the high single digits.
Zepbound的表現主要由自費通路(self-pay channel)持續強勁上升,以及商業保險(Commercial)族群的穩定成長所帶動。然而,部分州失去Medicaid給付資格,對第一季處方成長造成負面影響,幅度約為高個位數百分比。
We recently launched Zepbound in the US in a new equipment device that includes a full month of supply of medicine in one pen. Self-pays continues to be an important segment for Zepbound and accounted for approximately 45% of total Zepbound prescriptions in Q1 and 55% of new prescriptions.
我們近期在美國以新的給藥裝置推出Zepbound,該裝置以一支筆提供整整一個月的藥量。自費族群仍是Zepbound的重要區隔,第一季約占Zepbound總處方的45%,並占新處方的55%。
In the US, type 2 diabetes incretin analog market, total prescriptions grew 11% and Mounjaro gained another 3 percentage points of market share compared to the end of 2025. Outside the US, Mounjaro continues its steady progress within the incretin analog market.
在美國第二型糖尿病腸泌素類似物市場,總處方量成長11%,且Mounjaro相較於2025年底再提升3個百分點的市占。在美國以外,Mounjaro在腸泌素類似物市場中持續穩步推進。
Slide 10 shows aggregate trends in the international incretin analog market. The total international market has increased by 77% since the same period last year, as measured by IQVIA gross sales. In Q4 last year, Lilly came the market leader outside the US and the strong growth of Mounjaro in Brazil, UK, Korea, and China, among others, has resulted in additional share of market gains in Q1 2026. We expect continued strong performance outside the US but with share of market leadership already established, increased patient activations will be key to drive sustainable growth.
投影片10顯示國際腸泌素類似物市場的整體趨勢。依IQVIA總銷售額衡量,國際市場總量較去年同期增加77%。去年第四季,Lilly成為美國以外市場的領導者,而Mounjaro在巴西、英國、韓國與中國等地的強勁成長,使我們在2026年第一季進一步取得更多市占提升。我們預期美國以外仍將維持強勁表現;但在市占領導地位已建立的情況下,提升病患啟動將是推動可持續成長的關鍵。
Lastly, on slide 11 is an update of Foundayo launch. Early feedback from payers, physicians and patients is encouraging. Foundayo was broadly available in pharmacies on April 9 and is available on more than 12 major telehealth platforms. Discussions with payers have been productive and commercial access has been confirmed at two of the three largest US pharmacy benefit managers, effectively mid-May.
最後,投影片11為Foundayo上市進度更新。來自支付方、醫師與病患的早期回饋令人鼓舞。Foundayo已於4月9日在藥局廣泛供應,並已在超過12個主要遠距醫療平台上架。與支付方的討論進展順利,且在美國三大藥局福利管理機構(PBM)中的兩家已確認商業給付可及性,約於5月中旬生效。
In addition, the GLP-1 bridge program will start no later than July 1, which brings new access to anti-obesity medicines for people with insurance through Medicare. While HCP digital awareness campaigns went live shortly after approval, we began in-person promotion to HCPs on April 17.
此外,GLP-1銜接計畫(bridge program)將不晚於7月1日啟動,為透過Medicare投保的人群帶來新的抗肥胖藥物可及性。雖然HCP數位宣導活動在核准後不久即上線,我們已於4月17日開始對HCP進行實地推廣。
We expect to drive brand awareness and differentiation through full-scale consumer promotion, including direct-to-consumer TV advertising beginning in Q3. We are focused on commercial execution to drive long-term growth.
我們預期將透過全面性的消費者推廣(包含自第三季開始的直接面向消費者電視廣告)來提升品牌知名度並強化差異化。我們專注於商業執行,以推動長期成長。
On slide 12, we provide an update on capital allocation. Moving to slide 13, we share updated expectations for 2026 financial guidance. We have increased the top and the bottom end of the revenue range by $2 billion and now expect full-year revenue to be between $82 million and $85 billion. This reflects a strong underlying performance of Mounjaro and Zepbound in Q1. The midpoint of the new revenue range represents 28% growth compared to 2025.
在投影片12,我們提供資本配置的最新進展。接著到投影片13,我們分享更新後的2026年財務指引預期。我們將營收區間的上緣與下緣各上調20億美元,現預期全年營收介於820億至850億美元。此反映Mounjaro與Zepbound在第一季的強勁基本面表現。新營收區間的中位數相較2025年代表28%的成長。
We still expect price to be a headwind in the low to mid-teens for the full year. We expect our non-GAAP performance margin to be between 47% and 48.5%, driven by higher revenue. Our tax rate remains unchanged, and we now expect non-GAAP earnings per share of $35.50 to $37, an increase of $2 to the top and bottom of the non-GAAP earnings per share. We are pleased with our Q1 results and confident in our ability to deliver another year of industry-leading growth.
我們仍預期全年價格將帶來低至中十幾個百分點的逆風。我們預期非 GAAP 營業利潤率將介於 47% 至 48.5%,主要由較高營收所帶動。我們的稅率維持不變,且我們目前預期非 GAAP 每股盈餘為 35.50 至 37 美元,較先前預期的非 GAAP 每股盈餘上下限各上調 2 美元。我們對第一季的結果感到滿意,並對我們有能力再交出一年業界領先的成長充滿信心。
Now, I will turn the call over to Dan to highlight our progress on R&D.
現在,我將把電話會議交給 Dan,請他重點說明我們在研發方面的進展。
Daniel Skovronsky - Executive Vice President, Chief Scientific and Product Officer and President - Lilly Research Laboratories
Daniel Skovronsky - Executive Vice President, Chief Scientific and Product Officer and President - Lilly Research Laboratories
Thanks, Lucas. In our last earnings call, we've been busy with portfolio progression and significant business development in each of our major therapeutic areas. I'll share updates by area, beginning with cardiometabolic health. In addition to the US approval of Foundayo for obesity, we also announced positive top-line results from ACHIEVE 4, the seventh and final Phase 3 trial in our global registration programs for type 2 diabetes and obesity.
謝謝你,Lucas。在我們上次的財報電話會議之後,我們一直忙於產品組合推進,並在各主要治療領域進行了重大的業務開發。我將按領域分享最新進展,先從心臟代謝健康開始。除了 Foundayo 在美國獲准用於肥胖症之外,我們也公布了 ACHIEVE 4 的正向主要結果;該試驗是我們針對第二型糖尿病與肥胖症的全球註冊計畫中第七項也是最後一項第三期試驗。
This trial evaluated the time to first occurrence of MACE events for Foundayo compared to insulin glargine in adults with type 2 diabetes and obesity or overweight toward increased cardiovascular risk. As shown on slide 14, Foundayo met the primary endpoint of non-inferiority with a 16% lower risk of MACE four events. [And Foundayo demonstrated 23% lower risk in MACE three events.](corrected by company after the call)
此試驗評估在第二型糖尿病且合併肥胖或過重、並具有較高心血管風險的成人中,Foundayo 相較於胰島素 glargine 首次發生 MACE 事件的時間。如投影片 14 所示,Foundayo 達成主要終點的非劣性,MACE 四項事件風險降低 16%。[此外,Foundayo 在 MACE 三項事件上顯示風險降低 23%。](由公司於電話會議後更正)
Additionally, at a preplanned analysis not controlled for multiplicity, the survival advantage for patients of Foundayo was 57% compared to insulin glargine. These data add a new dimension to Foundayo's well-characterized effects on reducing A1c and weight as demonstrated in multiple previous Phase 3 trials.
另外,在一項預先規劃、但未進行多重性控制的分析中,Foundayo 患者相較於胰島素 glargine 的存活優勢為 57%。這些數據為 Foundayo 已被充分描述的降低 A1c 與體重效果增添了新的面向,該效果已在多項先前第三期試驗中證實。
Now with the results from ACHIEVE 4, cardiovascular safety and a lower risk of all-cause death are added to the clinical profile. Adverse events were generally consistent with other incretin-based therapies and no hepatic safety signals observed and ACHIEVE 4, nor across the seven positive Foundayo Phase 3 registrational trials.
如今隨著 ACHIEVE 4 的結果,心血管安全性以及全因死亡風險較低也被納入其臨床特徵。不良事件整體上與其他以腸泌素為基礎的療法一致;在 ACHIEVE 4 中未觀察到肝臟安全性訊號,在七項 Foundayo 第三期註冊性試驗的正向結果中亦未見相關訊號。
ACHIEVE 4 is also the last trial required for the US type 2 diabetes core registration package. We plan to complete the US submission for type 2 diabetes in late Q2 and anticipate regulatory action before the end of this year.
ACHIEVE 4 也是美國第二型糖尿病核心註冊申請資料包所需的最後一項試驗。我們計畫在第二季末完成美國針對第二型糖尿病的送件,並預期在今年年底前獲得監管機關的審查結果。
Moving to retatrutide, our GLP-1 and glucagon triple agonist, we announced positive top-line results from TRANSCEND-T2D-1, the first Phase 3 trial of retatrutide in people with type 2 diabetes. Given the potential counterregulatory impacts of glucagon activity on blood sugar control, we were excited to see profound improvements in hemoglobin A1c, as shown on slide 15.
接著談 retatrutide,我們的 GLP-1 與胰高血糖素三重致效劑;我們公布了 TRANSCEND-T2D-1 的正向主要結果,這是 retatrutide 在第二型糖尿病患者中的第一項第三期試驗。鑑於胰高血糖素活性可能對血糖控制產生反向調節影響,我們很高興看到糖化血色素 A1c 有顯著改善,如投影片 15 所示。
Compared to placebo, retatrutide lowered A1c by an average of 1.7 to 2.0 percentage points across doses. Importantly, we saw that participants lost an average of 11.1 to 16.6 kilograms or 25 to 37 pounds. While cross-trial comparisons of limitations, these data suggest retatrutide can deliver glycemic control in line with the most widely prescribed incretin therapy for type 2 diabetes, tirzepatide, while delivering additional weight loss.
與安慰劑相比,retatrutide 在各劑量下使 A1c 平均降低 1.7 至 2.0 個百分點。重要的是,我們看到受試者平均減重 11.1 至 16.6 公斤(或 25 至 37 磅)。雖然跨試驗比較有所限制,但這些數據顯示,retatrutide 在提供與第二型糖尿病最廣泛處方的腸泌素療法 tirzepatide 相當的血糖控制之同時,還能帶來額外的體重下降。
This is critically important given the difficulties people living with type 2 diabetes face when trying to lose weight and a significant need for better weight loss medications for this population. With these data in hand, we're optimistic that retatrutide can meet this need. Adverse events seen with retatrutide were generally consistent with what had been observed in clinical trials of incretin-based therapies and discontinuation rates due to adverse events were 5% or less across all arms. We look forward to presenting detailed TRANSCEND-T2D-1 results at the American Diabetes Association scientific sessions in June.
這點至關重要,因為第二型糖尿病患者在嘗試減重時面臨困難,而此族群對更佳減重藥物有顯著需求。有了這些數據,我們對 retatrutide 能滿足此需求感到樂觀。retatrutide 所見不良事件整體上與腸泌素為基礎療法臨床試驗中的觀察一致,且因不良事件而停藥的比例在所有組別皆為 5% 或以下。我們期待於 6 月的美國糖尿病學會科學年會上發表 TRANSCEND-T2D-1 的詳細結果。
Together with the positive TRIUMPH 4 results in obesity and knee osteoarthritis, we are beginning to establish a favorable clinical profile for retatrutide, consistent with our goals for this molecule. The next retatrutide trial to read out is TRIUMPH 1, an 80-week study in people with obesity. We look forward to sharing top-line results later this quarter.
結合在肥胖與膝骨關節炎方面的 TRIUMPH 4 正向結果,我們正開始為 retatrutide 建立有利的臨床特徵,符合我們對此分子的目標。下一項將公布結果的 retatrutide 試驗是 TRIUMPH 1,這是一項在肥胖人群中進行、為期 80 週的研究。我們期待在本季稍晚分享主要結果。
Also in cardiometabolic health, we initiated three additional Phase 3 programs for eloralintide. In addition to the ongoing Phase 3 obesity programs, we initiated Phase 3 programs in OA knee pain, obstructive sleep apnea, and as an add-on therapy for obesity.
在心臟代謝健康方面,我們也為 eloralintide 啟動了另外三項第三期計畫。除正在進行的第三期肥胖計畫外,我們也啟動了針對膝骨關節炎(OA)疼痛、阻塞型睡眠呼吸中止症,以及作為肥胖加成治療的第三期計畫。
As a selective amylin receptor agonist, or SARA, eloralintide has shown a unique profile of Phase 2 trials with GLP-1-like weight loss and improved tolerability. We're eager to explore additional indications for this promising molecule in what we expect to be a very robust Phase 3 program across a number of potential indications.
作為一種選擇性胰澱素受體致效劑(SARA),eloralintide 在第二期試驗中展現出獨特特徵:具有類 GLP-1 的減重效果,且耐受性更佳。我們期待在一項我們預期將非常強健的第三期計畫中,於多個潛在適應症上進一步探索這個具前景的分子。
We also recently completed our acquisition of Ventyx Biosciences, which brings a pipeline of small molecule therapeutics, including NLRP3 inhibitors designed to treat inflammation across a broad range of diseases. Both NLRP3 inhibitors are now shown in the Lilly pipeline. We also announced a licensing agreement with CSL for clazakizumab for certain indications, and that molecule will be reflected in our pipeline chart once Lilly trials have begun.
我們近期也完成對 Ventyx Biosciences 的收購,帶來一條小分子治療藥物的研發管線,其中包括旨在治療廣泛疾病發炎反應的 NLRP3 抑制劑。目前兩款 NLRP3 抑制劑都已列入 Lilly 的研發管線。我們也宣布與 CSL 就 clazakizumab 於特定適應症的授權協議;一旦 Lilly 的試驗啟動,該分子將反映在我們的研發管線圖表中。
Moving to immunology. We reported two important data sets for Ebglyss and atopic dosages. First, in the ADlong Phase 3b open-label extension study, Ebglyss delivered durable disease control for up to four years with [once per month maintenance] dosing. Nearly all patients achieved meaningful skin improvements, 75% achieved near complete skin clearance, and 80% maintaining their results without the need for topical, quote-unquote, steroids.
接著談免疫學。我們針對 Ebglyss 與異位性(相關)劑量報告了兩組重要數據。首先,在 ADlong 第三期 b 開放標籤延伸研究中,Ebglyss 以[每月一次維持]給藥可提供長達四年的持續疾病控制。幾乎所有患者都達到具意義的皮膚改善,75% 達到接近完全的皮膚清除,且 80% 在不需要外用、所謂的類固醇的情況下維持其結果。
For people living with chronic relapsing diseases like atopic dermatitis, sustained control delivered with convenience is the ultimate goal. We're pleased that our once every eight weeks maintenance regimen is currently under FDA review, and we expect regulatory action later this year. If approved, less frequent dosing may be a more convenient option to improve the patient experience and further differentiate Ebglyss from competitors.
對於罹患異位性皮膚炎等慢性反覆發作疾病的人而言,以便利方式達成持續控制是最終目標。我們很高興目前每 8 週一次的維持治療方案正由 FDA 審查中,並預期今年稍晚會有監管結果。若獲核准,較低頻率的給藥可能是更便利的選項,可改善患者體驗,並進一步使 Ebglyss 與競品區隔。
The second readout was the Phase 3 ADorable (inaudible) trial. Ebglyss delivered positive outcomes for children as young as six months old with moderate to severe atopic dermatitis. As shown on slide 16, 63% of children treated with Ebglyss achieved significant skin improvement as measured by EASI-75.
第二項讀出為第三期 ADorable(聽不清)試驗。Ebglyss 為最小僅 6 個月大、患有中度至重度異位性皮膚炎的兒童帶來正向結果。如投影片 16 所示,接受 Ebglyss 治療的兒童中有 63% 依 EASI-75 指標達到顯著皮膚改善。
In addition, 44% achieved clear or almost clear skin as endured by IGA (0,1) score. This makes Ebglyss the first and only selective IL-13 inhibitor with positive Phase 3 data in this age group where there are fewer approved medicines than in adolescents and adults. We plan to submit these data to regulators later this year for potential labels.
此外,有 44% 依 IGA(0,1)評分達到皮膚清除或幾乎清除。這使 Ebglyss 成為在此年齡層中第一個且唯一一個具有第三期正向數據的選擇性 IL-13 抑制劑;相較於青少年與成人,該年齡層可核准用藥更少。我們計畫於今年稍晚將這些數據提交監管機關,以爭取潛在的標示(適應症)擴增。
Also in immunology, reported positive top-line results from Jaypirca PSO the Phase 3b study of ixekizumab plus tirzepatide in adults with psoriasis and obesity. And together, PSO, 27% of participants on tirzepatide plus ixekizumab achieved the co-primary endpoint of total skin clearance and 10% or more weight loss compared to less than 6% of patients on ixekizumab alone.
在免疫學領域,我們也公布了 Jaypirca PSO 第 3b 期研究(在乾癬合併肥胖的成人中評估 ixekizumab 加上 tirzepatide)的正向主要(top-line)結果。此外,在 PSO 研究中,使用 tirzepatide 加 ixekizumab 的受試者有 27% 達成共同主要終點:皮膚完全清除且體重減輕至少 10%;相較之下,僅使用 ixekizumab 的患者達成率不到 6%。
These results are the second successful trial, highlighting the benefits of treating psoriatic disease and obesity with concomitant ixekizumab and tirzepatide therapy. This result provides further evidence that incretins may have a broader role in treating immunological diseases. We have additional ongoing Phase 2b combination trials in immunology studying ixekizumab plus tirzepatide in Crohn's disease and ulcerative colitis. We continue to assess other immunology settings where incretins may provide additional benefits.
這些結果是第二項成功的試驗,凸顯以 ixekizumab 與 tirzepatide 併用治療乾癬性疾病與肥胖的效益。此結果進一步證實,腸泌素(incretins)在治療免疫相關疾病方面可能具有更廣泛的角色。我們在免疫學領域另有正在進行的第 2b 期併用試驗,研究 ixekizumab 加 tirzepatide 用於克隆氏症與潰瘍性結腸炎。我們也持續評估其他免疫學情境,腸泌素可能在其中帶來額外效益。
We also announced business development in immunology with our agreement to acquire Orna Therapeutics. One's in vivo CAR T pipeline includes potential best-in-class programs to reset the immune system and address B-cell-driven autoimmune diseases. We look forward to exploring the full potential of Orna's platform together with the Orna team.
我們也宣布在免疫學領域的業務發展,已達成收購 Orna Therapeutics 的協議。Orna 的體內(in vivo)CAR T 產品線包含潛在同類最佳(best-in-class)的計畫,可望重置免疫系統並處理由 B 細胞驅動的自體免疫疾病。我們期待與 Orna 團隊共同探索 Orna 平台的全部潛力。
Turning to oncology. We announced positive top-line results from a Phase 3 pirtobrutinib trial, BRUIN CLL-322. This ambitious study evaluated pirtobrutinib in addition to a fixed duration regimen of venetoclax and rituximab in patients with previously treated CLL or SLL. Pirtobrutinib significantly extended progression-free survival compared to the fixed duration regimen and was the first medicine to utilize and outperform a venetoclax control containing control arm in a Phase 3 in the history of CLL drug development.
接著談腫瘤學。我們公布了 pirtobrutinib 第 3 期試驗 BRUIN CLL-322 的正向主要(top-line)結果。這項具企圖心的研究在既往治療過的 CLL 或 SLL 患者中,評估在固定療程的 venetoclax 與 rituximab 方案之外加用 pirtobrutinib 的效果。與固定療程方案相比,pirtobrutinib 顯著延長無惡化存活期(PFS),並且在 CLL 藥物開發史上,首次於第 3 期試驗中採用含 venetoclax 的對照組並取得優於對照的結果。
As shown on slide 17, pirtobrutinib has now been successful in four Phase 3 studies in CLL, each with compelling efficacy and profitability. Pirtobrutinib has been studied across early and later line settings of CLL, demonstrated efficacy as a monotherapy and in combination, and showed efficacy head-to-head against chemo immunotherapy, a covalent BTK inhibitor, and now a venetoclax-based regimen.
如投影片 17 所示,pirtobrutinib 目前已在 CLL 的四項第 3 期研究中取得成功,每一項都展現具說服力的療效與獲利能力。pirtobrutinib 已在 CLL 的早期與後線治療情境中進行研究,證實單藥與併用皆具療效,並在與化學免疫治療、共價型 BTK 抑制劑,以及如今的 venetoclax 為基礎之療程的頭對頭比較中展現療效。
The breadth of evidence suggests pirtobrutinib has potential to become a foundational therapy in CLL. Data from BRUIN CLL-313 and Brewin CLL-314 are currently under review by regulators for potential label expansion into the first-line setting. And we plan to submit the results of BRUIN CLL-322 to regulators later this year.
這些廣泛的證據顯示,pirtobrutinib 有潛力成為 CLL 的基礎性治療(foundational therapy)。BRUIN CLL-313 與 BRUIN CLL-314 的資料目前正由主管機關審查,以評估是否可將適應症標籤擴展至第一線治療。我們也計畫在今年稍晚將 BRUIN CLL-322 的結果提交主管機關。
Building on the breakthrough therapy designation received gene for platinum-resistant ovarian cancer, we initiated second Phase 3 trial of sofetabart's mipitecan, our fully receptor alpha in antibody zone conjugate to platinum-sensitive ovarian cancer.
在針對鉑類抗藥性卵巢癌取得突破性療法認定的基礎上,我們啟動了第二項第 3 期試驗,評估 sofetabart's mipitecan——我們的全人源化(fully)受體 alpha 抗體藥物複合體(antibody drug conjugate)——用於鉑類敏感性卵巢癌。
We also announced the acquisition of Kelonia Therapeutics. Kelonia's lentiviral in vivo CAR T platform, they showed very promising early clinical results in people with multiple myeloma, and we look forward to rapidly advancing the lead program with the Kelonia team as well as building future medicines using this technology platform. Earlier this week, we announced the acquisition of Ajax Therapeutics, the lead program, the Phase 1 JAK2 inhibitor for myelofibrosis and polycythemia vera builds on Lilly's established capabilities in blood cancer.
我們也宣布收購 Kelonia Therapeutics。Kelonia 的慢病毒(lentiviral)體內 CAR T 平台在多發性骨髓瘤患者中展現非常有前景的早期臨床結果;我們期待與 Kelonia 團隊迅速推進其領先計畫,並運用此技術平台打造未來藥物。本週稍早,我們宣布收購 Ajax Therapeutics;其領先計畫為用於骨髓纖維化與真性紅血球增多症的第 1 期 JAK2 抑制劑,將延伸禮來在血液腫瘤領域既有的能力。
Moving on to neuroscience. We initiated a Phase 3 program for brenipatide, or (inaudible) dual agonist in major depressive disorder. This trial will assess if brenipatide can delay time to relapse. With significant unmet need in psychiatry where rates remain high despite available treatments. We've also begun Phase 2 trials of brenepatide in opioid use disorder and schizophrenia, and initiated Phase 2 trials for two pain assets, a NAV 1.8 inhibitor and an AT2 receptor antagonist.
接著談神經科學。我們啟動 brenipatide(或(聽不清))在重度憂鬱症中的第 3 期計畫,該藥為雙重致效劑(dual agonist)。此試驗將評估 brenipatide 是否能延後復發時間。在精神醫學領域仍存在顯著未被滿足的需求,儘管已有可用治療,復發率仍然偏高。我們也已開始 brenepatide 在鴉片類物質使用障礙與思覺失調症的第 2 期試驗,並啟動兩項疼痛資產的第 2 期試驗:一項 NAV 1.8 抑制劑與一項 AT2 受體拮抗劑。
Lastly, we announced an agreement to acquire Centessa Pharmaceuticals, which will expand our neuroscience portfolio and capabilities into treating fleet disorders. Centessa, a leader in orexin science is advancing a pipeline of orexin receptor 2 agonists, the targeted neurobiological system governed in the fleet way cycle. The lead candidates, (inaudible), has demonstrated a potential best-in-class profile. We look forward to welcoming the Centessa team to Lilly later this year and continuing the development of these important molecules.
最後,我們宣布達成收購 Centessa Pharmaceuticals 的協議,將擴充我們的神經科學產品組合與能力,進一步延伸至治療 fleet disorders。Centessa 是食慾素(orexin)科學的領導者,正推進一系列食慾素受體 2(orexin receptor 2)致效劑的研發管線,該標的神經生物系統由 fleet way cycle 所調控。其領先候選藥物(聽不清)已展現潛在同類最佳(best-in-class)的特徵。我們期待在今年稍晚歡迎 Centessa 團隊加入禮來,並持續推進這些重要分子的開發。
Slide 18 shows pipeline movements since our last earnings call and slide 19 shows the full list of key events expected in 2026. I'll now turn the call back to Dave for closing.
投影片 18 顯示自上次財報電話會議以來的研發管線進展,投影片 19 則列出預計於 2026 年發生的所有關鍵事件。接下來我把電話交回 Dave 作結語。
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Thanks, Dan. We're pleased with the progress to start this year. We executed well both in driving business results and bringing new medicines to patients. We posted another quarter of impressive revenue and earnings growth.
謝謝你,Dan。我們對今年開局的進展感到滿意。我們在推動業務成果以及將新藥帶給病患兩方面都執行得很好。我們再度繳出一季亮眼的營收與獲利成長。
Shared top-line results from five positive Phase 3 trials, announced four acquisitions, initiated six new Phase 3 programs and launched an important new Lilly medicine. Productive quarter and yet a lot more to come in 2026.
我們分享了五項正向第 3 期試驗的主要(top-line)結果,宣布四項收購,啟動六項新的第 3 期計畫,並推出一款重要的禮來新藥。這是一個高產出的季度,而 2026 年還有更多值得期待。
Let me turn the call over now to Mike for the Q&A session.
現在我把電話交給 Mike 進行問答(Q&A)環節。
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Thank you, Dave. We'd like to take as many questions as possible. So consistent with prior quarters, please limit yourself to a single one-part question. Paul, please provide the instructions for how to join the queue and then we're ready for the first caller.
謝謝你,Dave。我們希望盡可能回答更多問題。因此,延續前幾季的做法,請各位只提出一個、且不拆分的問題。Paul,請提供如何加入提問隊列的說明,然後我們就準備接第一位來電者。
Operator
Operator
(Operator Instructions) Geoff Meacham, Citi.
(接線員指示)Geoff Meacham,花旗(Citi)。
Geoff Meacham - Analyst
Geoff Meacham - Analyst
Congrats on the quarter. Maybe this one is for Dave. Investors seem to be acutely focused on pricing and incretins with not a lot of emphasis on volume. I know you don't want to get too specific, but can you talk about, at a high level, the margins under a wide range of price scenarios for for Lilly? How do you see the investments you've already made in, say, manufacturing? And how does that add to the dynamic and what that means in terms of the competitive mote?
恭喜本季表現。這題也許是問 Dave 的。投資人似乎高度聚焦在定價與腸泌素(incretins),而對銷量的關注相對較少。我知道你不想講得太具體,但你能否從較高層次談談,在禮來面對各種不同價格情境下的毛利率表現?你如何看待你們已經投入的投資,例如製造端?這些因素如何影響整體動態,以及就競爭護城河而言代表什麼?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Great. Thanks, Geoff. Dave, do you want to take a few minutes to talk about pricing and incretins?
很好。謝謝你,Geoff。Dave,你願意花幾分鐘談談定價與腸泌素嗎?
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Sure. Thanks for the question, Geoff. Maybe a couple of things to point out, now that we're five or six quarters deep into the post-shortage world, and we can really pursue expansion on volume in an aggressive way. I think you can see something is a little different about the obesity and weight loss category from what we think about in other pharmaceuticals where the barrier is typically more informational not price sensitivity.
當然。謝謝你的問題,Geoff。也許先指出幾點:現在我們已進入缺貨後的世界大約五到六個季度,我們確實能以更積極的方式追求銷量擴張。我想你也看得出來,肥胖與減重這個類別與我們在其他藥品領域的思考有些不同;在其他領域,障礙通常更多是資訊面,而不是價格敏感度。
But here, clearly, because the out-of-pocket nature, 75% of ex US business for Mounjaro was out of pocket. US is a meaningful portion as well that we see quite expansionary volume, perhaps non-linear to price reductions. Of course, there's a floor on that, and we have sensitivity on our cost structures, et cetera. But pretty much every time we reduce pricing, we see a pretty large expansion.
但在這裡很明顯,因為自付(out-of-pocket)的特性,Mounjaro 在美國以外的業務有 75% 是自付。美國也占有相當比重;我們看到銷量擴張相當明顯,且可能對降價呈現非線性反應。當然,這其中有一個底線,我們也會考量成本結構等敏感性。但幾乎每一次我們降低價格,都會看到相當大的需求擴張。
You also see built into this, the primary pricing effect in Q1 are actually negotiated outcomes with governments, both the MFN package, we negotiated with the Trump administration. You cut out-of-pocket cost, you see strong growth. Like Lilly's up on vials really had quite a strong quarter in Q1 and with slightly lower prices.
你也可以看到,這裡面內建的主要定價影響在第一季其實是與政府談判的結果,包括最惠國(MFN)方案,我們與川普政府談判達成的。你降低自付費用,就會看到強勁成長。像禮來在小瓶裝(vials)方面第一季表現相當強勁,而且價格略低。
And then in China, we negotiated for diabetes access at a meaningful price reduction, but you can see the volume far outstripping the price concession. So kind of a different dynamic. And I think if investors can think about this category, perhaps unlike other pharmaceutic categories in the past.
然後在中國,我們就糖尿病可近性進行談判並做出有意義的降價,但你可以看到,銷量遠遠超過了價格讓步。所以算是不同的動態。我想如果投資人思考這個類別,或許會發現它不同於過去其他藥品類別。
In terms of margin sensitivity, it remains true that for this category for us at least, the unit economics are really driven by fixed costs that are either sunk in the past or unmovable depending on the volume in the present. And as a result, both covering the amortized R&D costs as well as CapEx is a concern from an accounting perspective. But at the margin, we do have latitude.
就毛利敏感度而言,對我們至少在這個類別上仍然成立的是,單位經濟性主要由固定成本所驅動,而這些固定成本要嘛是過去已沉沒、要嘛在當前取決於現有產量而難以移動。因此,從會計角度來看,涵蓋已攤銷的研發成本以及資本支出(CapEx)確實是一項考量。但在邊際上,我們確實有操作空間。
That said, we want to invest in future medicines. And I think that's probably the biggest, as we've said before, as we think about long-term operating margin for the company, the X factor. If we have good projects, we won't hesitate to invest in them, whether it be existing medicines, I think you see kind of a record load of Phase 3 NILEX at Lilly right now or for new medicines.
話雖如此,我們希望投資未來的藥物。我想這可能是我們之前說過的,當我們思考公司長期營業利益率時,最大的 X 因子。如果我們有好的專案,我們不會猶豫投入,不論是既有藥物——我想你現在看到禮來的第三期 NILEX 正處於某種創紀錄的負荷——或是新藥。
And we've got a very full Phase 2 and Phase 1 pipeline that we are deploying capital against. So we've got a lot of latitude here, Geoff, and I think this market works a little differently, and we're all sort of just getting used to that. But I think good news for Lilly and our incumbent position.
而且我們有非常充實的第二期與第一期研發管線,正在投入資本。所以我們在這裡有很大的彈性,Geoff。我想這個市場的運作方式有點不同,而我們大家也都在逐漸適應。但我認為這對禮來以及我們既有的領先地位是好消息。
Operator
Operator
Chris Schott, JPMorgan.
Chris Schott,摩根大通。
Christopher Schott - Analyst
Christopher Schott - Analyst
Congrats on the progress. I just wanted to dig a little bit more into international Mounjaro. And can you just share some of the learnings from -- I think it's been a much better expected launch than we all had anticipated here as we think about the ramp going forward and longer-term opportunity? And maybe as part of that, can you just -- should we expect any impact to the ramp from the entry of generic sema in select markets? Or is this such an early stage of penetration where that's less relevant?
恭喜進展。我想再深入了解一下國際市場的 Mounjaro。你能否分享一些經驗——我想就我們對未來放量與長期機會的看法而言,這次上市的表現比大家原先預期好得多——有哪些學到的東西?另外作為其中一部分,你能否說明——在部分市場引入學名藥 sema 之後,我們是否應該預期會對放量造成任何影響?還是說目前滲透仍很早期,因此影響相對不大?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Great. Thanks, Chris. For the question about international Mounjaro and the potential impact of generic sema. We'll go to Patrik.
很好。謝謝你,Chris。關於國際市場 Mounjaro 以及學名藥 sema 的潛在影響這個問題,我們請 Patrik 回答。
Patrik Jonsson - Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Patrik Jonsson - Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Thank you very much, Chris. When we look at the first quarter, it's truly a strong growth of all our prioritized products across international, but of course, particularly in Mounjaro. And now we have fully launched in more than 55 countries, and we have seen a very strong speed of uptake and also a rapid market share gain. Also in the month, we launched the second half of 2025, referring to Brazil, in Korea, where we currently have an estimated market share of 60%. And of course, also the China type 2 NRDL reimbursement.
非常感謝你,Chris。回顧第一季,我們所有在國際市場優先推動的產品都呈現強勁成長,當然尤其是 Mounjaro。目前我們已在超過 55 個國家全面上市,並看到非常快的採用速度以及迅速的市占提升。另外在本月,我們在 2025 年下半年推出的市場也已上市,指的是巴西;以及在韓國,我們目前估計市占約 60%。當然也包括中國第二型糖尿病納入 NRDL 給付。
When we look at the generics, we only have a few weeks of data from India, but it seems like it's really stimulating the growth in the overall obesity market. And that includes our product. And the Mounjaro has actually been holding market share quite nicely. When we look at the Mounjaro prescriptions, they are about 10% higher in recent weeks compared to the period prior to generic center. So I think it just underscores that dual agonist trumps single agonist.
就學名藥而言,我們只有來自印度的幾週數據,但看起來它確實在刺激整體肥胖市場的成長。這也包含我們的產品。而 Mounjaro 的市占其實維持得相當不錯。從 Mounjaro 的處方量來看,最近幾週比學名藥進入前的期間高出約 10%。所以我想這再次凸顯:雙重致效劑勝過單一致效劑。
Moving forward, I think we should expect a very strong continued year-on-year growth and some sequential growth. We saw in the slide earlier that we have a market share above 53% OUS, and that's an average. And in many international markets, we have a market share along the lines of what we see in the US with Zepbound. And when you get to that level of share, incremental share gain is getting harder. And of course, we will focus our efforts on patient activation, driving increased penetration in the chronic weight managed market and end market growth.
展望未來,我認為我們應該預期非常強勁的年對年持續成長,以及一定程度的季對季成長。我們在先前的投影片看到,海外(OUS)的平均市占已超過 53%。在許多國際市場,我們的市占水準與美國 Zepbound 所見相近。當你達到那樣的市占水準時,要再進一步提升增量市占就會更難。當然,我們會把重點放在病患啟動(patient activation)、推動慢性體重管理市場的滲透提升,以及終端市場成長。
And also secondly, what we have seen during the second half of the year has been some seasonality, mainly driven by the holiday season in Europe, where patients tend to take a holiday -- drug holiday break or actually delay the initiation of the new therapy start. But overall, strong growth across regions. Seems like generic semaglutide is stimulating market growth, and we continue to do well. We expect a continued strong year-on-year growth, sequential growth driven by patient activation.
另外第二點,我們在下半年看到一些季節性因素,主要由歐洲的假期季帶動,病患往往會放「用藥假期」——暫停用藥——或是延後開始新的治療。但整體而言,各區域都呈現強勁成長。看起來學名 semaglutide 正在刺激市場成長,而我們的表現仍然良好。我們預期年對年將持續強勁成長,季對季成長則由病患啟動所驅動。
Operator
Operator
Seamus Fernandez, Guggenheim.
Seamus Fernandez,Guggenheim。
Seamus Fernandez - Equity Analyst
Seamus Fernandez - Equity Analyst
Great. So really, we just wanted to get a better understanding of how the market as you see it is starting to segment and could segment going forward? More as you look forward to the potential introduction of retatrutide amidst the Foundayo launch as well as then the follow-on to that being the (inaudible), where do you see the market really opening up with each of these potential assets reaching forward?
很好。我們主要想更清楚了解,依你們的觀察,市場如何開始分眾,以及未來可能如何分眾?特別是展望 retatrutide 可能導入、同時 Foundayo 上市,以及其後續(聽不清)之後,你們認為隨著這些潛在資產逐步到位,市場會如何真正被打開?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Great. Thanks, Seamus. For that question, we'll go to Ken to talk a bit about the broad lead portfolio and how we see the market segmenting.
很好。謝謝你,Seamus。針對這個問題,我們請 Ken 談談更廣泛的領先產品組合,以及我們如何看待市場分眾。
Kenneth Custer - Executive Vice President and President - Lilly Cardiometabolic Health
Kenneth Custer - Executive Vice President and President - Lilly Cardiometabolic Health
Yeah, sure. Thanks for the question, Seamus. I think it's reasonable to expect in this large and growing market and opportunity in obesity that with the number of patients around the world living with overweight or obesity numbering perhaps in the billions, but many of them are going to want different types of medicines that are tailored to their individual needs and preferences.
好的,當然。謝謝你的問題,Seamus。我認為在這個龐大且持續成長的肥胖市場與機會中,合理的預期是:全球有過重或肥胖的病患人數可能以十億計,但其中許多人會想要不同類型、能依其個別需求與偏好量身打造的藥物。
We're in early innings in that regard. We're now sort of bringing the third segment, I guess, in. We've had GLP-1 single agonist and then dual-agonists and now oral medicines, but we see many other sort of plausible opportunities to tailor medicines to different groups.
在這方面我們仍處於非常早期的階段。我們現在大概是在引入第三個分眾。我們先有 GLP-1 單一致效劑,接著是雙重致效劑,現在是口服藥物,但我們也看到許多其他合理的機會,可以把藥物更精準地對應不同族群。
As you noted, retatrutide is one of those ideas, which very obviously could play to individuals who are seeing greater weight loss, although I will say we see opportunities for retatrutide elsewhere and across the spectrum of obesity.
如你所提到的,retatrutide 就是其中一個想法,它很明顯可能適用於希望達到更大減重幅度的個體;不過我也要說,我們也看到 retatrutide 在其他地方、以及在肥胖光譜各個區段的機會。
Eloralintide, we can position that a few ways based on the Phase 2 data that we've seen. The first of which is that this could be a great medicine for patients seeking a non-GLP-1 based mechanism, perhaps due to tolerability of experience or tolerability that they are fearful of. It may also be a good drug that could be added on top of existing incretin therapies to provide incremental weight lowering.
Eloralintide 依據我們看到的第二期數據,可以用幾種方式來定位。第一,它可能是對於尋求非 GLP-1 機轉的病患而言很好的藥物,或許是因為他們對耐受性體驗不佳,或是擔心耐受性問題。它也可能是一個可加在既有腸泌素(incretin)療法之上的好藥物,以提供額外的體重下降效果。
But there's many other ideas out there Lilly is investing in. That includes medicines to a veto even less frequently, perhaps those that dial in addition -- excuse me, additional metabolic benefits and maybe some that are sort of ultra-long acting using genetic medicine approaches. We see all of these as compelling ideas. And we also feel we're in a leading position in most, if not all, of those spaces.
但還有許多其他想法是禮來正在投資的。其中包括給藥頻率更低的藥物;也包括那些能帶來——不好意思——額外代謝效益的方案;以及一些可能採用基因藥物(genetic medicine)方法、具超長效作用的藥物。我們認為這些都是很有吸引力的想法。而且我們也認為,在大多數、甚至所有這些領域,我們都處於領先位置。
In terms of how the market will ultimately shake out in terms of percentage of use across those different ideas, it's hard to prognosticate that, but many of these ideas are tied to common manufacturing platforms and we're making the investments to support any of them should they prove to be really the most favorable option for managing (inaudible).
就市場最終會如何在這些不同構想之間、以使用占比的形式分化而言,很難預測;但其中許多構想都繫於共同的製造平台,而我們正在進行投資,以便在它們之中任何一個若被證明是管理(聽不清)的最有利選項時,都能提供支援。
Operator
Operator
Alex Hammond, Wolfe Research.
Alex Hammond,Wolfe Research。
Alexandria Hammond - Equity Analyst
Alexandria Hammond - Equity Analyst
On Medicare access, can you walk us your strategy to activate these patients? And when do you kind of see this playing out in terms of either maybe a 4Q dynamic or more of a 2027 as these patients pull through? And I guess, as well, with the attractive price point, how do you think about persistence in this population?
關於 Medicare 的可近性,能否帶我們了解你們啟動這些病患的策略?以及你們大概何時會看到這件事的落地——可能是第 4 季的動態,或是更偏向 2027 年、隨著這些病患逐步導入?另外,我想也問一下,在具吸引力的價格點之下,你們如何看待這個族群的持續用藥(persistence)?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Okay. Thanks, Alex, for the question about Medicare access and sort of staging over time, we'll go to Ilya.
好的。謝謝你,Alex,關於 Medicare 可近性以及隨時間推進的分階段問題,我們請 Ilya 來回答。
Ilya Yuffa - Executive Vice President, President of Lilly International
Ilya Yuffa - Executive Vice President, President of Lilly International
Yeah. Great. Thank you for the question. Obviously, we're excited about having Part D access starting to activate for obesity medicines starting in July. And the way that we think about it, there are little or deep beneficiaries that are able (inaudible) so the path to that with having a long trajectory with the bridge program of starting in July through 2027 is an important aspect.
是的。很好。謝謝你的提問。顯然,我們對於 Part D 對肥胖藥物的給付可近性將自 7 月開始啟動感到振奮。我們的看法是,會有一些受益人能夠(聽不清),因此透過自 7 月開始一路延伸到 2027 年的橋接計畫、形成較長的推進軌跡,是很重要的一環。
Obviously, that will take time to build. We need to have the education across physician-based pharmacies as well as consumer base to understand the whole half of different medicines that we have and available for treating obesity. And so that will be a gradual path in '26 as it starts and then continued growth in '27.
顯然,這需要時間來建立。我們需要在以醫師為基礎的藥局以及消費者端進行教育,讓大家理解我們有哪些不同藥物、以及可用於治療肥胖的完整方案。因此,這會是在 2026 年啟動後逐步推進的路徑,並在 2027 年持續成長。
And obviously, the $50 month co-pay is an important element of affordability for seniors. We've already seen for Zepbound as well as Mounjaro. We've had great persistency overall relative to other chronic conditions and we continue to see that. Obviously, the $50 co-pay and affordability will only just add to that in addition to all of the health benefits and experiences that people will have over time. So we're excited about expanding access very soon.
而且很明顯,每月 50 美元的自付額(co-pay)是提升長者可負擔性的重要要素。我們在 Zepbound 以及 Mounjaro 上已經看到,整體持續用藥表現相較其他慢性疾病非常好,而且我們仍持續看到這樣的趨勢。顯然,50 美元自付額與可負擔性只會進一步強化這點,此外還有民眾隨時間累積的各種健康效益與使用體驗。因此,我們對於很快擴大可近性感到興奮。
Operator
Operator
Evan Seigerman, BMO Capital.
Evan Seigerman,BMO Capital。
Evan Seigerman - Analyst
Evan Seigerman - Analyst
Bigger picture, strategically, as you think about the next levers of growth for the business, what do you need to see from either the I&I, neuroscience or oncology franchises to kind of match the scale of the obesity metabolic businesses or particular assets? Is it BD or something else?
從更宏觀的策略角度來看,當你們思考公司下一波成長槓桿時,你們需要從 I&I、神經科學或腫瘤產品線看到什麼,才能在規模上與肥胖/代謝業務或特定資產相匹配?會是 BD(商務開發)或其他方式嗎?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Great. Thanks, Evan. We'll go to Dan to talk about some of the important programs that he's focused on to drive growth in the future.
很好。謝謝你,Evan。我們請 Dan 來談談他所聚焦、用以推動未來成長的一些重要計畫。
Daniel Skovronsky - Executive Vice President, Chief Scientific and Product Officer and President - Lilly Research Laboratories
Daniel Skovronsky - Executive Vice President, Chief Scientific and Product Officer and President - Lilly Research Laboratories
Yeah. Thanks, Evan, for that question, and it's an important one to us. It's hard to say, you're asking about scale, but I point out in growth rate those businesses are growing extremely fast. Even without the obesity and metabolic business, Lilly would be the fastest or certainly one of the fastest-growing pharmaceutical companies in the industry.
是的。謝謝你,Evan,這個問題對我們很重要。很難直接回答,因為你問的是規模,但我想指出,就成長率而言,那些業務成長非常快。即使不包含肥胖與代謝業務,Lilly 也會是業界成長最快、或至少是成長最快之一的製藥公司。
So we're proud of what we're doing in those three areas. And I think each of them has very significant unmet medical needs that we can scale into as our medicines are successful. So we like what we got. We like the direction we're going.
所以我們對於在這三個領域所做的事情感到自豪。我認為每個領域都有非常顯著、尚未被滿足的醫療需求;隨著我們的藥物成功,我們可以把規模做上去。所以我們喜歡我們手上的布局。我們也喜歡我們前進的方向。
Of course, in each of those areas, we also see opportunities to get a lot bigger, and we've highlighted some of the themes already in the areas. You'll also see us address some of that through business development. So for example, the Centessa acquisition allows us to play in a new area here in sleep wake medicines. The Orna acquisition allows us to play in new areas of immune reset for example.
當然,在每個領域我們也看到把規模做得更大的機會,而且我們已經在這些領域中強調過一些主題。你們也會看到我們透過商務開發來處理其中一部分。例如,收購 Centessa 讓我們能在睡眠—覺醒(sleep-wake)藥物這個新領域布局。收購 Orna 則讓我們能切入例如免疫重置等新領域。
Operator
Operator
Asad Heider, Goldman Sachs.
Asad Heider,Goldman Sachs。
Asad Haider - Analyst
Asad Haider - Analyst
Congrats on the continued strong execution. Maybe just going back to Foundayo. Appreciate all the color on early launch dynamics, which is sort of playing out along the lines of your messaging that the initial launch trajectory is going to live below that of oral (inaudible), but then there's going to be an acceleration as we move into the back half of the year.
恭喜持續強勁的執行表現。我想回到 Foundayo。感謝你們提供關於早期上市動態的許多細節;這大致符合你們先前的訊息:初期上市軌跡會低於口服(聽不清),但隨著進入下半年會加速。
So just now with a few weeks of launch under your belt, I think you said 15,000 patients have started taking the drug already. What's your level of confidence on that launch curve framing in the context of the early experience?
那麼在上市幾週之後,我想你們提到已經有 15,000 名病患開始用藥。在早期經驗的背景下,你們對於這條上市曲線的描述有多大信心?
And then related on the guidance range, are you able to provide any high-level commentary on what type of contribution was factored in for Foundayo, recognizing that you said that the revised range reflects mainly the strong underlying performance of Mounjaro and Zepbound?
另外,關於指引區間,你們是否能提供任何高層次的評論:在指引中為 Foundayo 納入了何種程度的貢獻?同時也理解你們說過,這次上修區間主要反映 Mounjaro 與 Zepbound 強勁的基本面表現。
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Great. Thanks for the question, Asad. Ilya, do you want to talk about some of the early launch metrics that you're tracking and the feedback you're hearing? And then maybe just a short comment from Lucas about the guide?
很好。謝謝你的問題,Asad。Ilya,你願意談談你們正在追蹤的一些早期上市指標,以及你們聽到的回饋嗎?然後也許請 Lucas 簡短評論一下指引?
Ilya Yuffa - Executive Vice President, President of Lilly International
Ilya Yuffa - Executive Vice President, President of Lilly International
Sure. Well, first, it is early days, but we're pretty pleased with the trajectory and encouraging first start to launch. Obviously, we just started active sales force promotion just over a week ago, having broad availability in the supply channel just two weeks ago. Really, we're encouraged by the initial leading indicators.
當然。首先,現在還是早期,但我們對於目前的走勢相當滿意,上市初期的起步也令人鼓舞。顯然,我們大約一週多前才開始由業務團隊進行積極推廣,而供應通路在兩週前才剛全面到貨。整體而言,我們對初期的領先指標感到鼓舞。
And the way that we think about it, there are probably three key factors and catalysts of growth. And those three are: one, growing the familiarity among healthcare providers on the clinical profile of Foundayo, building out the access, and growing the awareness of Foundayo with consumers. And we're making progress on all three fronts.
我們的看法是,可能有三個關鍵因素與成長催化劑。這三個是:第一,提高醫療照護提供者對 Foundayo 臨床特性的熟悉度;第二,建立可近性;第三,提高消費者對 Foundayo 的認知。我們在這三個面向都在取得進展。
And so on HCPs, if you think out the early indicators, we now have over 8,000 prescribers of Foundayo, a third of which who have not previously written an oral GLP-1. And so this is expansive, and the current sentiment so far what we're hearing is really positive on the overall efficacy and kind of the no-hassle factor on a daily oral GLP-1. So that's an important aspect.
以醫療照護提供者(HCP)來看,若你把早期指標攤開來看,我們現在已有超過 8,000 位 Foundayo 的開立者,其中三分之一過去從未開立過口服 GLP-1。因此這是在擴大覆蓋;而目前我們聽到的情緒與回饋,在整體療效以及每日口服 GLP-1 的「省事/無負擔」特性上都非常正面。這是一個重要面向。
We'll continue on the execution related to HCPs around sampling, continued promotions through our sales force, as well as educational seminars. And we're fully in the field with our promotional offers with HCPs. So good progress there.
我們會持續在 HCP 端推進執行,包括提供試用(sampling)、透過業務團隊持續推廣,以及教育研討會。我們也已在第一線全面推出針對 HCP 的推廣方案。所以這方面進展良好。
On access, we've confirmed commercial access at two of the large PBMs as by middle of May, so just in a couple of weeks. And to the earlier question on Medicare, Medicare Access will start at the beginning of July. And so those are continued catalyst of growth upcoming in the next couple of months. And so we see that as an important unlock and expansion as well.
在可近性方面,我們已確認截至 5 月中旬,兩家大型 PBM 已提供商業保險可近性,也就是再過幾週。而呼應先前關於 Medicare 的問題,Medicare 可近性將在 7 月初開始。因此,未來幾個月還會有持續的成長催化劑出現。我們也將其視為重要的解鎖點與擴張動能。
And then on the third piece on consumer front, we now have just over 20,000 patients treated to date. And what important element there is that 80% of those found prescriptions are new to class. So this is expansive in bringing new people into being treated for overweight or obesity.
至於第三部分、消費者端,我們目前累計已治療超過 20,000 名病患。其中一個重要點是,這些 Foundayo 處方中有 80% 是該治療類別的新使用者(new to class)。因此,這是在擴大範圍,把新的人群帶入超重或肥胖的治療。
We've done a number of aspects already around the direct-to-consumer on digital, social media and others. But obviously, we will continue those efforts on a full-scale direct-to-consumer and TV launch in Q3. Important there is just to ensure that prescribers have familiarity around the profile of Foundayo before we do that.
我們已經在數位、社群媒體等面向,針對直接面向消費者(DTC)做了多項工作。但很明顯地,我們將在第三季以全面規模持續推進這些努力,並進行DTC與電視的上市推廣。其中重要的是,在我們這麼做之前,要確保處方醫師對Foundayo的產品特性(profile)有足夠的熟悉度。
So bottom line, I think we're pleased with the progress. Early indicators are positive and moving in the right direction. And the trajectory will build over time. This is a new brand, new medicine we're bringing to the market. So we're pleased and ready to go.
所以總結來說,我認為我們對進展感到滿意。早期指標是正面的,且正朝正確方向前進。而這個走勢會隨時間逐步建立。這是一個我們帶入市場的新品牌、新藥品。因此我們感到滿意,也已準備就緒。
Lucas Montarce - Chief Financial Officer, Executive Vice President
Lucas Montarce - Chief Financial Officer, Executive Vice President
Maybe on the second part going to the guidance, Asad. Just to highlight a couple of things. Of course, again, the increase on our guidance is driven by the strength of the entire portfolio that we mentioned during the call, starting, of course, with the increase in portfolio, both in the US and our US.
也許就指引(guidance)的第二部分來說,Asad。我想強調幾點。當然,再次說明,我們上調指引是由我們在電話會議中提到的整體產品組合強勁表現所驅動,當然首先來自產品組合的成長,無論是在美國以及我們的美國(業務)。
In terms of Foundayo per se, you've heard already from Ilya about how we continue to see progress and very encouraging feedback that we hear from payers, physicians and patients as well. We set up the plan at the beginning of the year, and it's very early days. We have three weeks of data at this time. So it's tracking to our expectations, and we will continue to see how this progresses over the year, but we feel very confident on the trajectory that we've seen so far.
就Foundayo本身而言,你已經聽Ilya提到,我們持續看到進展,且從付款方、醫師以及病患那裡也聽到非常令人鼓舞的回饋。我們在年初就制定了計畫,而目前仍是非常早期的階段。截至目前我們只有三週的數據。因此其表現符合我們的預期;我們會持續觀察今年的進展,但對目前看到的走勢非常有信心。
Operator
Operator
James Shin, Deutsche Bank.
James Shin,德意志銀行。
James Shin - Research Analyst
James Shin - Research Analyst
This one for Dave. With bridge extending into 2027, Dave, what's the next for balance? Is Lilly working with stakeholders on revisions to secure longer-term Medicare access?
這題給Dave。Bridge延長到2027年後,Dave,接下來在平衡(balance)方面會怎麼走?Lilly是否正與利害關係人合作修訂,以確保更長期的Medicare可及性?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Thanks, James. Dave, do you want to share a few comments about the bridge balance dynamics?
謝謝你,James。Dave,你想分享一些關於Bridge平衡動態的看法嗎?
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Sure. Yeah. Look, when we signed the agreement with the administration, we all knew Bridge was going to be put in place because it was a midyear launch. And we had understood at the time that there was a commitment to '27, if as a contingency, the Part D plans did not choose to opt in at a certain rate.
當然。是的。你看,當我們與政府簽署協議時,我們都知道Bridge會被設置,因為那是年中上市。而我們當時也理解,如果作為一項或有安排(contingency),Part D計畫未以一定比例選擇加入,則會承諾延續到2027年。
Of course, we now know they didn't. And maybe that's not so surprising. They operate on our margins. There's been other disturbances and market events in the Part D program, for instance, the I-pay products, et cetera, that have changed their economics. And unfortunately, I guess, not being a part of those discussions, but they couldn't cross with the major players for calendar '27. So the government is doing what they said and they're extending bridge.
當然,我們現在知道他們沒有加入。而這或許也不那麼令人意外。他們是在我們的利潤空間上運作。Part D計畫中也出現了其他干擾與市場事件,例如I-pay產品等等,改變了他們的經濟性。而不幸的是,我想,因為我並未參與那些討論,但他們無法在2027年日曆年度與主要參與者達成一致。所以政府正在履行其承諾,延長Bridge。
I think for manufacturers, there's some puts and takes in that. But the fact that there'll be access to the consumers at $50 a month, I think, is a very compelling proposition. As Ilya highlighted before, will drive great persistency. And in an 18-month window, I think we will start to see population-level health improvements if these are used at scale.
我認為對製造商而言,這其中有一些利弊權衡。但能讓消費者以每月50美元取得可及性,我認為是非常有吸引力的主張。正如Ilya先前強調的,這將帶來很高的持續用藥率(persistency)。而在18個月的窗口期內,如果這些藥物能以規模化方式使用,我認為我們將開始看到族群層級的健康改善。
That will then set up the '28 discussion. I would expect the government to lean hard into getting Part D plan participation in '28 and normalizing obesity care as a standard preventative treatment and something that should be used to treat comorbidities of obesity within the senior population. We may have the evidence to support that as we exit '27. It may need a little more time, but I think they're going to push to help make that happen.
這將為2028年的討論奠定基礎。我預期政府會在2028年大力推動Part D計畫參與,並將肥胖照護常態化,作為標準的預防性治療,以及用於治療高齡族群中與肥胖相關的共病。當我們走出2027年時,可能會有證據支持這一點。也可能還需要多一點時間,但我認為他們會推動促成此事。
And I think that normalization is overdue in the commercial market. So it will be a good leading indicator for us across the US business. We'll continue to work with the government closely through that period and, of course, try to work with them to activate patients and make sure they can find success on our medicines. So stay tuned, probably more news as we exit '26 on the actual '28 plans.
而我認為在商業市場中,這種常態化早就該發生了。因此,這將成為我們在美國業務上的一個很好的領先指標。在此期間我們會持續與政府密切合作,當然也會努力與他們合作,啟動病患並確保他們能在我們的藥物上獲得成功。所以請持續關注,可能在我們接近2026年底時,會有更多關於實際2028年計畫的消息。
Operator
Operator
Mohit Bansal, Wells Fargo.
Mohit Bansal,富國銀行。
Mohit Bansal - Analyst
Mohit Bansal - Analyst
Congrats on the progress. I just want to touch upon the Employer Connect program that you are embarking upon. So it seems like the insurance -- our commercial insurance has been relatively stable-ish year-over-year.
恭喜進展。我想談談你們正在推動的Employer Connect計畫。看起來保險——我們的商業保險在年對年方面相對穩定。
So this seems to be the way to grow it and employees are worried about their cost long term and everything. So would love to understand what are the steps to convince employers to buy in into the Employer Connect program and the mechanics of it?
所以這似乎是成長的方式,而員工也擔心他們的長期成本等等。因此很想了解,說服雇主加入Employer Connect計畫的步驟是什麼,以及其運作機制?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Thanks, Mohit. Ilya, do you want to make a few comments about Employer Connect and the progress and focus?
謝謝你,Mohit。Ilya,你想就Employer Connect的進展與重點談幾點嗎?
Ilya Yuffa - Executive Vice President, President of Lilly International
Ilya Yuffa - Executive Vice President, President of Lilly International
Sure. Thanks, Mohit. Yeah. Listen, as you mentioned, the overall commercial access has been pretty steady, around 50%. And one of the key aspects that we're excited about is having an Employer Connect platform, where we work with a number of third parties to actually go out and talk to different employers about the value of covering obesity care.
當然。謝謝你,Mohit。是的。如你所提,整體商業可及性一直相當穩定,大約在50%左右。而我們很興奮的一個關鍵面向,是建立Employer Connect平台;我們與多家第三方合作,實際走出去與不同雇主溝通,說明涵蓋肥胖照護的價值。
But there are several consider -- a little bit different with our Employer Connect program. One is a transparent price that is known to all of the employers and providing the flexibility and design around the employer/employee contribution towards obesity coverage. And so we do think that this is a positive element to increase the number of employers to opting in.
但我們的Employer Connect計畫有幾個考量——也有些不同之處。其一是透明的價格,讓所有雇主都清楚,並在雇主/員工對肥胖保障的分攤(contribution)上提供彈性與設計空間。因此我們確實認為,這是提高雇主選擇加入數量的一個正面因素。
Obviously, the selling cycle timeline for making decisions for '26 has already passed. So while we are currently having positive conversations and positive feedback from employers around this new platform, that will most likely have a gradual impact in the back half of '26 and most likely incremental opt-ins for '27.
顯然,針對2026年的決策銷售週期時程已經過了。因此,雖然我們目前與雇主的對話與回饋都很正面,但這個新平台的影響很可能會在2026年下半年逐步顯現,並且更可能在2027年帶來額外的加入(opt-ins)。
And then as part of that, obviously, there's more data on real evidence and also components of where employers do cover what are the benefits to their employees overall, both in their health and productivity over time. And as that data comes out, that will only reinforce the positive decision to provide coverage for obesity care.
此外,隨著更多真實世界證據(real-world evidence)數據出來,以及在雇主確實提供涵蓋時,對員工整體效益的各項要素——包括健康與生產力隨時間的改善——當這些數據公布後,只會進一步強化提供肥胖照護保障的正向決策。
Operator
Operator
Terence Flynn, Morgan Stanley.
Terence Flynn,摩根士丹利。
Terence Flynn - Analyst
Terence Flynn - Analyst
Congrats on all the progress. I had a question broadly. You talked to the portfolio that you're going to be -- you currently have, but you're also rolling out across the incretin area. And so as you think about the evolution, I guess, of the DTC channel, what are some of the things you're considering to kind of leverage Lilly's scale in that channel? And then also anything that you think will help there from the commercial side in terms of driving additional coverage in terms of having scale across the portfolio?
恭喜各項進展。我有一個較宏觀的問題。你談到你們將要——目前已擁有的產品組合,但你們也正在incretin領域持續推出。因此當你思考DTC通路的演進時,你們正在考量哪些事項,以便在該通路中槓桿運用Lilly的規模?另外,從商業端來看,有沒有什麼你認為能在推動額外涵蓋方面提供幫助,例如在整體產品組合上形成規模效應?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Thanks for the question, Terence. We're going to Dave to talk a bit about the portfolio strategy and leveraging DTC.
謝謝你的問題,Terence。我們請Dave談談產品組合策略以及如何槓桿運用DTC。
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Sure. And Ilya and Patrik can jump in here. I think you're pointing out something that as you've all been developing part of the story here for our growth, which is consumers wanting to take charge of their own health and activate the digital platforms to control weight and obesity.
好的。Ilya和Patrik也可以在這裡補充。我認為你指出了一點:你們大家一直在為我們成長的故事鋪陳的一部分,也就是消費者希望掌握自身健康,並啟用數位平台來管理體重與肥胖。
I think this is here to stay, and it's a big part of our business now and probably something we need to continue to invest in. We're doing just that. So you should expect continuous improvement in that experience for consumers in the US and then expansion nationally with the current offerings.
我認為這會長期存在,而且現在已是我們業務的重要部分,可能也是我們需要持續投入的領域。我們正是這麼做的。因此,你應該會看到在美國消費者端的體驗持續改善,並在現有產品組合的基礎上擴展至全國。
I would also say this notion as we move into other kinds of medicines that could be more preventative could be quite a useful platform to reach more people. We all know that the financing of the current healthcare system has to struggle everywhere. And with all the noise around PAs and other barriers to care people need people want to take into their own hands. And I think, of course, we need to do that within the confines of the regulations in law, but there's a lot of room for improvement for consumers, and it's a great outlet potentially for us.
我也想說,當我們進入其他可能更偏向預防性的藥物領域時,這個平台概念可能會非常有用,能觸及更多人。我們都知道,現行醫療體系的融資在各地都必須艱難應對。而且在事前授權(PA)以及其他就醫障礙的各種雜音之下,人們需要、也想把一些事情掌握在自己手中。當然,我認為我們必須在法規與法律的框架內來做,但對消費者而言仍有很大的改善空間,對我們來說也可能是一個很好的出口。
So let me ask Ilya or Patrik to add to that if they have anything to add on Lilly Direct and our offerings.
所以我想請 Ilya 或 Patrik 如果有任何補充,針對 Lilly Direct 以及我們的產品提供再加一些說明。
Ilya Yuffa - Executive Vice President, President of Lilly International
Ilya Yuffa - Executive Vice President, President of Lilly International
Yeah. Sure. Just maybe a few key components of what we've seen on Lilly Direct. With Zepbound, you've seen that currently, around 55% of new patient starts are coming through self-pay for most of which is coming through the direct or telehealth players, which is a component of reducing some of the frictions in place.
好的。當然。我可能就我們在 Lilly Direct 上看到的情況,提幾個關鍵組成部分。以 Zepbound 而言,你會看到目前約 55% 的新病患起始用藥來自自費,其中大多數是透過直營或遠距醫療(telehealth)業者,這有助於降低現有的一些摩擦。
And even early in our launch of Foundayo with limited promotion, we're seeing that reduced friction level and understanding direct-to-consumer is an important number. About 45% of our volume for Foundayo early on is coming through Lilly Direct. And so we continue to look at ways to improve on the experience both providers and for consumers in the way they get their health and enter their journey for disease, and obviously, it plays a significant role for obesity currently.
而且即使在我們以有限推廣推出 Foundayo 的早期,我們也看到摩擦程度降低,並且理解直面消費者(DTC)是個重要指標。Foundayo 早期約 45% 的量是透過 Lilly Direct 進來的。因此我們持續尋找方法,改善醫療提供者與消費者的體驗,讓他們取得健康服務並開始其疾病旅程;顯然,這在目前的肥胖症領域扮演重要角色。
Patrik Jonsson - Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Patrik Jonsson - Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Similarly outside of US, I referred earlier to us being at a very high market share in most of the markets already. And patient activation is going to drive the most of the coming growth. And we have seen that the markets are responding to patient vaccination efforts, although it's a slower ramp, but that's going to be key, taking into account the low penetration of incretins outside of the US.
同樣地,在美國以外,我先前提到我們在多數市場已經擁有非常高的市占率。而病患啟動(patient activation)將推動接下來的大部分成長。我們也看到各市場對病患接種疫苗的推動措施有所回應,雖然爬坡較慢,但這將是關鍵,尤其考量到美國以外腸泌素(incretins)的滲透率仍偏低。
Operator
Operator
Umer Raffat, Evercore.
Umer Raffat,Evercore。
Umer Raffat - Equity Analyst
Umer Raffat - Equity Analyst
I thought I'll spend a quick second on Zepbound's commercial dynamics in US. And really, what I'm trying to understand is, for example, 1Q $7 million TRx and $4.1 billion sales for Zepbound in US, meaning it's about $580 per prescription.
我想花一點時間談談 Zepbound 在美國的商業動態。我真正想了解的是,例如第一季 700 萬張 TRx、以及 Zepbound 在美國 41 億美元銷售額,意味著每張處方約 580 美元。
And even if you adjust for some of the one-time adjustments, it's still about $550 per Rx, whereas we understand the cash pay prices to be about $450 or so I mean that prices too. I guess what explains that delta or maybe IMS is just not capturing some of your online channels?
即使你把一些一次性調整因素扣除,每張 Rx 仍約 550 美元;但我們理解現金自費價格大約是 450 美元左右——我的意思是價格也是如此。我想問的是,這個差異是怎麼來的?還是說 IMS 只是沒有捕捉到你們部分線上通路?
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Lucas to talk a bit about the pricing dynamics in the US.
請 Lucas 談一下美國的定價動態。
Lucas Montarce - Chief Financial Officer, Executive Vice President
Lucas Montarce - Chief Financial Officer, Executive Vice President
Yeah, Umer, thank you for your question and quick math that your math is pretty spot on, by the way. So -- just to highlight, yes, and even normalizing by these peer-to-peer adjustments. First of all, again, going back to the initial question on pricing, if you carve out what we agreed on MFN side as well back in November and then the NRDL access prices has been relatively stable quarter-on-quarter.
好的,Umer,謝謝你的提問,也謝謝你快速的計算;順帶一提,你的數學算得很準。所以——先強調一下,是的,即使把這些同儕間(peer-to-peer)的調整因素標準化。首先,再回到最初關於定價的問題,如果你把我們在 11 月就 MFN 方面達成的內容切割出去,再加上 NRDL 准入價格,季度對季度來看一直相對穩定。
I think it's going back to what we discussed last time about maintaining that price discipline. We continue to see that happening while we continue to grow significantly on the volume side as well.
我認為這回到我們上次討論的:維持價格紀律。我們持續看到這點在發生,同時我們在量的面向也持續顯著成長。
And yes, again, going back to your analysis on the pricing, yes, you have the Lilly Direct prices that, as you know, we have adjusted down starting in December. And those prices have been very stable on that front as well. And then the rest, basically by difference, you get into the commercial business, mainly that that's the different portion that it gets to that net $550 that you highlighted.
而且是的,再回到你對定價的分析:是的,你有 Lilly Direct 的價格,如你所知,我們從 12 月開始已向下調整。而這部分的價格也一直非常穩定。其餘的部分,基本上以差額來看,就會進入商業端業務,主要就是那一塊差異,使其達到你提到的 550 美元淨價。
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Maybe just one add, I think it isn't widely appreciated is there is a reasonable amount of medical exception and OSA usage that moves across channels at close to an undiscounted price. So I think that's probably the piece of your math you might want to take a look at.
我再補充一點:我認為外界並未普遍意識到的是,存在相當比例的醫療例外(medical exception)與 OSA 使用情境,會跨通路流動,且價格接近未折扣價。所以我想那可能就是你計算中需要再看一下的那一塊。
Operator
Operator
Courtney Breen, Bernstein.
Courtney Breen,Bernstein。
Courtney Breen - Equity Analyst
Courtney Breen - Equity Analyst
I know there's been a huge amount of focus on kind of the first few weeks of Foundayo and specifically kind of the launch strategy and activation of the different channels. Perhaps, Ken, it would be helpful if you could talk through how does this compare to kind of a traditional primary care launch?
我知道市場非常聚焦在 Foundayo 上市最初幾週,特別是上市策略以及不同通路的啟動。也許 Ken,如果你能說明一下,這與傳統的基層醫療(primary care)上市相比如何,會很有幫助?
What things are you accelerating? What things are you holding back and for what reasons, particularly in the context of the fact that you've got extreme amounts of inventory pre-prepared for the launch of this product?
你們有哪些事情在加速?又有哪些事情在按住不做、以及原因是什麼?尤其是在你們為這個產品上市預先準備了極大量庫存的背景下。
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Okay. Thanks, Courtney. Ilya, do you want to make a few more comments about the Foundayo launch vis-a-vis primary care?
好的。謝謝你,Courtney。Ilya,你要不要就 Foundayo 的上市相對於基層醫療,再多做一些評論?
Ilya Yuffa - Executive Vice President, President of Lilly International
Ilya Yuffa - Executive Vice President, President of Lilly International
Sure. Again, maybe just probably the three elements I discussed earlier are probably the same for all of our primary care launches where you need to grow the prescriber base and understanding of the profile of the medicine, and that's what we're doing here with Foundayo, building out access. And quite frankly, this is actually gaining access very early in launch, both on the commercial side, having two of the three being activated in the next couple of weeks and getting Part D, which is usually lags in July is a faster ramp on access, and so we're excited about that aspect.
當然。再說一次,可能我先前提到的三個要素,對我們所有基層醫療的上市都一樣:你需要擴大開立處方醫師的基礎,並讓大家理解藥物的特性;這正是我們在 Foundayo 上所做的,同時建立准入。坦白說,這次在上市初期就取得准入其實進展很快:在商業端,三個中的兩個會在接下來幾週內啟動;而 Part D 的取得通常會在 7 月才落後跟上,這次在准入上爬坡更快,所以我們對這一點感到興奮。
The piece that is probably on the primary care side, an important element that many have noted around DTC. And we activated from day one in the first week, a number of both digital, social media, and out-of-home advertising on the brand itself. But it does take time to build out consumer understanding and awareness of the brand.
而在基層醫療端,許多人提到的一個重要要素是直面消費者(DTC)。我們從第一天、第一週就啟動了多項品牌層面的宣傳,包括數位、社群媒體以及戶外廣告。但建立消費者對品牌的理解與認知仍需要時間。
The current sentiment, if you follow the total number of impressions and what consumers are saying about the profile Foundayo, is resonating. So both the efficacy as well as the overall profile on not having food and water restrictions. And so that element is positive.
目前的情緒面,如果你追蹤總曝光量以及消費者對 Foundayo 特性所說的內容,是有共鳴的。也就是療效以及整體特性——不需要食物與飲水限制。因此這個面向是正面的。
Now obviously, having full DTC launch, we're still activating that probably earlier than normal because there is familiarity around GLP-1, but we do want to take a moment and have to be disciplined in the approach of making sure that physicians actually understand what Foundayo is before activating fully. But overall, this is following an accelerated path in primary care.
當然,若要全面啟動 DTC 上市,我們確實仍在推進,而且可能比一般更早,因為市場對 GLP-1 已有熟悉度;但我們也希望稍微停一下,並在方法上保持紀律,確保醫師在我們全面啟動前,確實理解 Foundayo 是什麼。但整體而言,這在基層醫療上是一條加速的路徑。
And if I compare, we've had the opportunity to launch many brands within primary care with Trulicity, with Mounjaro, Zepbound, Jardiance, all of which have gone towards leadership in those categories in a competitive space. So we feel pretty good about all of the actions we're taking, the three key factors and the pace at which we are activating all three components.
如果我做個比較,我們在基層醫療領域有機會推出過許多品牌,包括 Trulicity、Mounjaro、Zepbound、Jardiance,這些都在競爭激烈的領域中走向類別領導地位。因此我們對正在採取的所有行動、三個關鍵因素,以及我們啟動這三個組成部分的速度,都相當有信心。
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
(inaudible) just to reiterate one thing, which we said earlier, but just so it's not lost, the three major products that are used in obesity in the United States are all line extensions. So the molecule was on the market before. And in some cases, the brand name was used before.
(聽不清)我只是想重申一點,我們先前提過,但為了不讓它被忽略:在美國用於肥胖症的三個主要產品全部都是線延伸(line extensions)。也就是說,該分子先前就已在市場上。而在某些情況下,品牌名稱先前也曾使用過。
So consumer awareness, which is the brand name and the molecule itself, which is the physician part, we're starting from a much lower baseline. We've got to build that, but we're hugely confident we'll be able to build it. We've launched many, many primary care drugs that are new successfully.
因此,消費者認知——也就是品牌名稱;以及分子本身——也就是醫師端——我們是從一個低得多的基準起步。我們必須把這些建立起來,但我們非常有信心能夠做到。我們已成功推出許多全新的基層醫療用藥。
And then the final thing I'll say is that related to your inventory. I mean that really speaks to the international rollout. That's why we keep mentioning there's 40 different countries under review, and we expect that to happen also in one of the most accelerated cadences perhaps in the history of the industry.
最後我想說的一點是,這也與你的庫存相關。我的意思是,這其實反映了國際上市的推進。這就是為什麼我們一直提到有 40 個不同國家正在審查中,而且我們預期這也將以可能是業界史上最加速的節奏之一發生。
So expect launches as we exit this year into next year in quite scaled markets. And we know from what we're seeing on this call with Mounjaro and international, there's a huge opportunity for Foundayo around the world.
因此,當我們從今年結束進入明年時,請預期會在相當具規模的市場推出上市。而且從我們在這通電話中看到的 Mounjaro 與國際市場的情況,我們知道 Foundayo 在全球有巨大的機會。
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Great. One last quick question, and then we'll go to the close.
很好。最後一個簡短問題,然後我們就進入結語。
Operator
Operator
Dave Risinger, Leerink.
Dave Risinger,Leerink。
David Risinger - Analyst
David Risinger - Analyst
So Dave, I was hoping that you could just frame your vision for employer coverage in the United States. So in the US pharmaceutical business, employer coverage is most important for drugs, particularly drugs that treat various medical conditions beyond cosmetic.
Dave,我希望你能簡要說明你對美國雇主給付(保險涵蓋)的願景。在美國藥品市場中,雇主給付對藥品非常重要,特別是治療各種醫療狀況、而非僅屬美容用途的藥物。
And so I understand that you have the employer direct initiative, but I'm just trying to get my head around what you think will happen with regular employer insurance coverage in coming years versus coverage that will involve greater cost sharing by participants that engage with Lilly Direct for consumers to pay more out of pocket than they are paying today under regular employer coverage?
因此,我理解你們有 Employer Direct 的倡議,但我想釐清的是:你認為未來幾年一般雇主保險的常規給付會如何發展?相較之下,是否會出現更多由參與者分攤成本的給付方式——也就是透過 Lilly Direct 的管道,讓消費者自付額比目前在一般雇主給付下支付的更多?
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
Okay. Thanks, Dave, for the question. Obviously, an important factor in -- we do think, just as a policy matter, that obesity and overweight medications should be broadly covered. I think a big step in this journey is actually the July 1 Medicare. There's often spillover benefits into commercial from there. And I think setting a standard that people in America should expect if they've paid into their insurance program or their employer has that will cover their health needs.
好的。謝謝你,Dave,提出這個問題。顯然,這是一個重要因素——我們確實認為,從政策角度來看,肥胖與過重用藥應該被廣泛納入給付。我認為這段旅程中的一大步其實是 7 月 1 日的 Medicare(醫療保險)。從那裡往往會對商業保險產生外溢效益。我也認為,這是在建立一個標準:美國民眾應該期待,如果他們已繳納保費進入其保險計畫,或其雇主提供保險,那就應該能涵蓋其健康需求。
That said, I think the likely path from here to what I think will ultimately begin to look like other chronic medication markets like diabetes and hypertension, I think we will get there with this category. But it won't be a straight line. It won't be a straight line. It won't be kind of everything we want on day one.
話雖如此,我認為從現在到最終——也就是這個市場開始看起來像其他慢性用藥市場(例如糖尿病與高血壓)——我們會在這個類別達到那一步。但這不會是一條直線。不會是一條直線。也不會在第一天就得到我們想要的一切。
Why? Because the economics you're mentioning, it's a very broad disease. 70% of adults have overweight or obesity and potential candidates for these medications. And it's the last thing in. And we know that despite the fact that it could be one of the most valuable healthcare interventions available, it's the last one we see, so it's easier to say no to.
為什麼?因為你提到的經濟性:這是一種非常普遍的疾病。70% 的成年人有過重或肥胖,且可能是這些藥物的候選人。而且這是最後才被納入的項目。我們也知道,儘管它可能是最有價值的醫療介入之一,但它卻是我們最後才看到的,因此更容易被拒絕。
But we do see progress there. As Ilya said, Employer Direct is all about creating new options to get to yes with employers, alternate pathways. We'll continue to publish data, as I'm sure Novo-Nordisk will that demonstrate that pretty much all of these drugs in this category have had profound effects and are probably cost effective at their current prices. And of course, prices have been trending down.
但我們確實看到進展。正如 Ilya 所說,Employer Direct 的核心是在為雇主創造新的選項,以便更容易「點頭同意」——提供替代途徑。我們會持續發布數據,我相信 Novo Nordisk 也會,來證明這個類別中幾乎所有藥物都帶來深遠效果,並且在目前價格下很可能具成本效益。當然,價格也一直呈下降趨勢。
So we'll continue to make progress. I should also say we have a number of new indications coming. And per Umer's question earlier, that actually is a pretty good unlock for us when we get in directly-indicated populations with acute comorbid disease. So all those things are pulled together and in some future year, we'll look back and say we got there. But it's going to be more incremental progress quarter-on-quarter. And we'll keep updating the Street with what to expect as we issue our guidance.
因此我們會持續推進。我也要補充,我們有多個新的適應症即將到來。而且呼應先前 Umer 的問題,當我們能在具有急性共病疾病、且為直接適應症的人群中切入時,這其實對我們而言是一個相當好的解鎖點。所以把這些因素綜合起來,在未來某一年,我們回頭看會說:我們做到了。但這將會是按季逐步、循序漸進的進展。而且在我們發布財測指引時,我們會持續向市場更新可預期的情況。
Michael Czapar - Senior Vice President of Investor Relations
Michael Czapar - Senior Vice President of Investor Relations
Dave, do you want to do a couple of comments to close?
Dave,你要不要做幾點結語?
David Ricks - Chairman of the Board, President, Chief Executive Officer
David Ricks - Chairman of the Board, President, Chief Executive Officer
I will. So again, I appreciate everyone dialing in today on our call and your interest in Eli Lilly and Company. We hope you'll join us later this year. We're announcing a Lilly investment community update day. This will be on Monday, December 7, and details on location and exact timing are to follow. Please follow up with the IR team if you have any questions that we didn't address today, and hope you have a great day. Thanks.
我會。再次感謝各位今天撥入參加我們的電話會議,也感謝大家對禮來公司(Eli Lilly and Company)的關注。我們希望各位在今年稍晚也能加入我們。我們將宣布舉辦一場 Lilly 投資人社群更新日。時間是 12 月 7 日(週一),地點與確切時間等細節將另行公布。如果各位對今天未能涵蓋的問題有任何疑問,請與投資人關係(IR)團隊聯繫,也祝各位有美好的一天。謝謝。
Operator
Operator
Thank you. And ladies and gentlemen, this does conclude our conference for today. This conference will be made available for replay beginning at 1 PM today running through June 4 at midnight. You may access the replay system at any time by dialing (800) 332-6854 and entering the access code 662964.
謝謝。各位女士先生,今天的電話會議到此結束。本次會議的重播將於今天下午 1 點開始提供,並持續至 6 月 4 日午夜。你可隨時撥打 (800) 332-6854 並輸入存取碼 662964 以收聽重播系統。
International dialers can call (973) 528-0005. Again, those numbers are (800) 332-6854, and (973) 528-0005 with the access code 662964. Thank you for your participation. You may now disconnect your lines.
國際撥入者可致電 (973) 528-0005。再次提醒,電話號碼為 (800) 332-6854 與 (973) 528-0005,存取碼為 662964。感謝各位的參與。你現在可以掛斷電話線。